Gilead Sciences
NASDAQ: GILD
Gilead Sciences develops and sells innovative medicines for HIV, viral hepatitis, cancer and inflammatory diseases. Its virology business, particularly HIV treatments and prevention medicines, is a major part of the company's pharmaceutical business, while its oncology business focuses on cancer therapies.
- Sector
- Health Technology
- Industry
- Biotechnology
- Employees
- 17,000
- Founded
- 1987
- Website
- gilead.com ↗
The forecast figures are tipranks’s, read on 2026-11-16 and linked below.
The company facts and financials are CNN Business’s, read on 2026-11-16 and linked below.
Gilead Sciences forecast
The forecast in short
tipranks records 23 analyst ratings on Gilead Sciences and summarises them as “Strong Buy”. Their average 12-month price target is USD 173.76 (3.38% Upside). Its tipranks score is 10 out of 10 — Outperform. These are tipranks’s figures as read on 2026-11-16, not CariBroker’s own view, and nothing here is advice to buy or sell.
Market cap
USD 209.59 B
≈ RM 857.36 B
Share price
USD 168.98
≈ RM 691.23 · 18 Nov close
#83World ranking
tipranks score
Outperform
Analyst ratings
Strong Buy
- Buy1878%
- Hold522%
- Sell00%
tipranks’s own summary of the 23 ratings above.
12 months price forecast
USD 173.76 3.38% Upside
As tipranks publishes it. CariBroker has not recalculated any of it.
Financials
Q3 earnings, quarter ending Sep 29, 2026
| Measure | Q3 2026 | 1-year change |
|---|---|---|
| Total revenue | 8.30B | 4.39% up |
| Net income | 2.43B | 11.27% up |
| Earnings per share | 1.94 | 20.22% down |
| Net profit margin | 29.25% | 25.40% down |
| Free cash flow | 4.80B | 53.68% up |
| Debt-to-equity ratio | 2.01 | 73.75% up |
Revenue and net income, last 4 quarters
Total revenueNet income
Analyst profiles: who made each call, and when
| Analyst | From | Position | Target price | Dated |
|---|---|---|---|---|
| Jasper Hellweg | Argus Research | Buy | USD 190 | 2026-11-11 |
| Louise Chen | Scotiabank | Buy | USD 200 | 2026-11-10 |
| Michael Okunewitch | Maxim Group | Buy | N/A | 2026-11-05 |
| Brian Abrahams | RBC Capital | Hold | USD 131 | 2026-11-05 |
| Geoff Meacham | Citi | Buy | USD 188 | 2026-11-04 |
Show all 24
| Analyst | From | Position | Target price | Dated |
|---|---|---|---|---|
| Evan Seigerman | BMO Capital | Buy | USD 184 | 2026-11-02 |
| Daina Graybosch | Leerink Partners | Hold | USD 145 | 2026-11-02 |
| Mohit Bansal | Wells Fargo | Buy | USD 190 | 2026-10-30 |
| Joseph Stringer | Needham | Buy | USD 200 | 2026-10-30 |
| Michael Yee | UBS | Buy | USD 195 | 2026-10-30 |
| Terence Flynn | Morgan Stanley | Buy | USD 183 | 2026-10-30 |
| Tyler Van Buren | TD Cowen | Buy | USD 175 | 2026-10-30 |
| Chris Schott | J.P. Morgan | Buy | USD 190 | 2026-10-30 |
| Gregory Renza | Truist Financial | Buy | USD 181 | 2026-10-30 |
| Umer Raffat | Evercore ISI | Buy | N/A | 2026-10-30 |
| Carter Gould | Cantor Fitzgerald | Buy | USD 175 | 2026-10-29 |
| Salveen Richter | Goldman Sachs | Hold | USD 155 | 2026-10-29 |
| Emily Field | Barclays | Hold | USD 145 | 2026-10-28 |
| Brian Skorney | Robert W. Baird | Hold | USD 145 | 2026-10-27 |
| Courtney Breen | Bernstein | Buy | USD 160 | 2026-10-25 |
| Tazeen Ahmad | Bank of America Securities | Buy | USD 172 | 2026-10-20 |
| Morten Herholdt | HSBC | Buy | USD 175 | 2026-09-10 |
| Salim Syed | Mizuho Securities | Buy | USD 170 | 2026-08-31 |
| Akash Tewari | Jefferies | Buy | USD 180 | 2026-05-22 |
Investment strengths
Strong cash generation
Exceptionally strong operating and free cash flow provides financial resilience even when reported earnings are weak. This supports continued investment in research and development, funding for launches, debt servicing, and shareholder returns without relying solely on external financing.
HIV franchise momentum
The HIV franchise combines recurring chronic-treatment demand with strong product adoption and market leadership. Growth in Biktarvy, prevention products, and newer options such as Yeztugo gives Gilead a durable commercial base and supports continued cash generation.
Pipeline diversification
A broad pipeline across several therapeutic areas can reduce dependence on any single product or franchise over time. Continued development in oncology and inflammation, alongside multiple long-acting HIV programs, improves the company’s prospects for renewing growth.
People also ask
What is the 12-month price target for Gilead Sciences (GILD)?
tipranks publishes an average 12-month price target of USD 173.76 (3.38% Upside), as read on 2026-11-16. The highest target is USD 200 and the lowest is USD 131. A price target is an analyst’s estimate of where a share might trade, not a promise, and CariBroker gives no investment advice.
How many analysts cover Gilead Sciences (GILD)?
tipranks records 23 analyst ratings: 18 buy, 5 hold and 0 sell, which it summarises as “Strong Buy”, as read on 2026-11-16.
What is the tipranks score for Gilead Sciences (GILD)?
tipranks scores it 10 out of 10 and calls that “Outperform”, as read on 2026-11-16. The score is tipranks’s, not CariBroker’s, and CariBroker does not rate listed shares.
Is this CariBroker’s own forecast for Gilead Sciences?
No. Every figure on this page is published by tipranks, copied on 2026-11-16 with a link to the original, and not recalculated. CariBroker checks financial companies in Malaysia against the public registers; it makes no forecast of its own and holds no licence to advise on securities.
Disclaimer
CariBroker provides information only and does not provide investment, financial or legal advice.
Check another company
Search every bank, broker and alert list in one place
